PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
8.27%
Positive revenue growth while 3391.T is negative. John Neff might see a notable competitive edge here.
11.47%
Positive gross profit growth while 3391.T is negative. John Neff would see a clear operational edge over the competitor.
16.10%
Positive EBIT growth while 3391.T is negative. John Neff might see a substantial edge in operational management.
15.53%
Positive operating income growth while 3391.T is negative. John Neff might view this as a competitive edge in operations.
12.54%
Positive net income growth while 3391.T is negative. John Neff might see a big relative performance advantage.
12.53%
Positive EPS growth while 3391.T is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
12.53%
Positive diluted EPS growth while 3391.T is negative. John Neff might view this as a strong relative advantage in controlling dilution.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
81.38%
10Y revenue/share CAGR above 1.5x 3391.T's 30.39%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
81.38%
5Y revenue/share CAGR above 1.5x 3391.T's 30.39%. David Dodd would look for consistent product or market expansions fueling outperformance.
63.60%
3Y revenue/share CAGR above 1.5x 3391.T's 23.26%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
-100.00%
Negative 10Y OCF/share CAGR while 3391.T stands at 100.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-100.00%
Negative 5Y OCF/share CAGR while 3391.T is at 100.00%. Joel Greenblatt would question the firm’s operational model or cost structure.
-100.00%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
95.12%
Net income/share CAGR at 50-75% of 3391.T's 168.38%. Martin Whitman might question if the firm’s product or cost base lags behind.
95.12%
5Y net income/share CAGR at 50-75% of 3391.T's 168.38%. Martin Whitman might see a shortfall in operational efficiency or brand power.
58.16%
Below 50% of 3391.T's 270.87%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
124.82%
10Y equity/share CAGR above 1.5x 3391.T's 54.04%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
124.82%
5Y equity/share CAGR above 1.5x 3391.T's 54.04%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
84.15%
3Y equity/share CAGR above 1.5x 3391.T's 41.94%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
-50.00%
Cut dividends over 10 years while 3391.T stands at 42676.20%. Joel Greenblatt suspects a weaker ability to return capital vs. the competitor.
-50.00%
Negative 5Y dividend/share CAGR while 3391.T stands at 42676.20%. Joel Greenblatt sees a weaker commitment to dividends vs. a competitor that might be growing them.
30.43%
Below 50% of 3391.T's 52010.91%. Michael Burry suspects the firm invests elsewhere or can’t match the competitor’s dividend policy.
22462.50%
AR growth well above 3391.T's 4.19%. Michael Burry fears inflated revenue or higher default risk in the near future.
4.04%
Inventory growth well above 3391.T's 2.51%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
13.63%
Asset growth above 1.5x 3391.T's 6.37%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
5.35%
1.25-1.5x 3391.T's 4.29%. Bruce Berkowitz sees if the firm's capital management strategies surpass the competitor's approach.
141.03%
Debt growth far above 3391.T's 11.46%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-26.00%
We cut SG&A while 3391.T invests at 2.06%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.